Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Bacterial Conjunctivitis

Summary

A Phase 2, Multi-center, Randomized, Parallel Controlled Study to Evaluate the Clinical Efficacy and Safety of IVIEW-1201 (1.0% Povidone-Iodine) Gel Forming Ophthalmic Solution Compared to Ofloxacin Eye Drops in the Treatment of Acute Bacterial Conjunctivitis

Timeline

Start

2023-01-05

Primary completion

2023-11-13

Completion

2024-10-12

Outcome

Met primary endpoint

registry analysis (non-inferiority test); IVIEW-1201 vs Ofloxacin Eye Drops; p = 0.0137; Chi-squared NCT05816070 ↗

release “positive topline result in the Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis” iviewtherapeutics.com ↗

release “The prespecified primary endpoint (clinical cure rate at Day 8) of non-inferiority to Ofloxacin achieved.” iviewtherapeutics.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Ofloxacin	Small molecule	—	Other
Subject	Povidone-Iodine	Other / unclassified	1 %	Other

Indications